¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ ÁøÇ༺ À¯¹æ¾ÏÀÇ ¼Ò¶óÆä´Õ°ú È­ÇÐ ¿ä¹ý(Combining Sorafenib with Chemotherapy ) º´¿ë Ä¡·áÈ¿°ú
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

ÀÓ»óÁú¹® (Clinical Queastion)

Q: ¼Ò¶óÆä´Õ°ú È­ÇÐ ¿ä¹ý(Combining Sorafenib with Chemotherapy )À» º´¿ëÇÏ´Â Ä¡·á¸¦ HER2 (human epidermal growth factor receptor 2) À½¼º ÁøÇ༺ À¯¹æ¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î Àû¿ëÇÏ¿© Ä¡·áÇÏ¿´À» ¶§  ¼Ò¶óÆä´ÕÀÇ È¿´É ¹× ¾ÈÀü¼ºÀ» °ËÁõÇÑ ¿¬±¸°á°ú°¡ ÀÖ½À´Ï±î?

 

±Ù°Å±â¹Ý ´äº¯

 

A: sorafenib°ú È­Çпä¹ýÀ» ÇÔ²²ÇÑ ±×·ì°ú placebo plus chemotherapy µÎ±ºÀÇ È¿´É°ú ¾ÈÀü¼ºÀ» ºñ±³Çϱâ À§ÇÏ¿© 844¸íÀÇ HER2 (human epidermal growth factor receptor 2) À½¼º ÁøÇ༺ À¯¹æ¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î RCT¿¬±¸¸¦ ¸ÞŸºÐ¼®ÇÑ °á°ú, ¼Ò¶óÆä´Õ ±ºÀÌ ´ëÁ¶±ºº¸´Ù progression-free survival (PFS), time to progression (TTP)°¡ ´õ ±æ°Ô ³ªÅ¸³µÀ¸¸ç, overall response rate (ORR)°ú ÀÓ»óÀ¯ÀÍÀº ´õ¿í ³ô°Ô ³ªÅ¸³µ´Ù.  ±×·¯³ª ¼Õ¹ß ÇǺΠ¹ÝÀÀ / ¼Õ ¹ß ÁõÈıº (HFS / HFS), ¼³»ç, ¹ßÁø, °íÇ÷¾Ð ¹× ±¸³»¿° ¹ßº´·ü µîÀÇ ºÎÀÛ¿ëÀÌ ¼Ò¶óÆä´Õ±º¿¡¼­ ´õ¿í À¯ÀÇÇÏ°Ô ³ô¾ÒÀ½À» º¸°íÇÏ¿´½À´Ï´Ù.

 

 

Ãâó :

Efficacy and Safety Profile of Combining Sorafenib with Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer: A Meta-analysis

Journal of Breast Cancer, 2014³â 17±Ç 1È£ p.61~68,

https://doi.org/10.4048/jbc.2014.17.1.61


2018-03-07 ¿ÀÀü 10:12:20, Á¶È¸¼ö : 1934